248 related articles for article (PubMed ID: 19274429)
21. Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
Bavaro DF; De Vito A; Pasculli G; Bouba Y; Magnasco L; Pincino R; Saladini F; Lattanzio R; Corsini R; Arima S; Zazzi M; Incardona F; Rossetti B; Bezenchek A; Vanni B; Di Biagio A
J Med Virol; 2022 Aug; 94(8):3890-3899. PubMed ID: 35355293
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness of antiretroviral regimens containing abacavir with tenofovir in treatment-experienced patients: predictors of virological response and drug resistance evolution in a multi-cohort study.
Di Giambenedetto S; Torti C; Prosperi M; Manca N; Lapadula G; Paraninfo G; Ladisa N; Zazzi M; Trezzi M; Cicconi P; Corsi P; Nasta P; Cauda R; De Luca A; ; ;
Infection; 2009 Oct; 37(5):438-44. PubMed ID: 19669091
[TBL] [Abstract][Full Text] [Related]
23. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia.
Li JZ; Gallien S; Do TD; Martin JN; Deeks S; Kuritzkes DR; Hatano H
Antimicrob Agents Chemother; 2012 Nov; 56(11):5998-6000. PubMed ID: 22890763
[TBL] [Abstract][Full Text] [Related]
24. [Clinical use of HIV-1 resistance genotyping. Predictive factors of poor virological evolution in salvage treatments].
Riera-Jaume M; Peñaranda-Vera M; Ribas-Blanco MA; Murillas-Angoiti J; Campins A; Salas-Aparicio A; Leyes-García M; Pareja-Bezares A; Pérez JL; Villalonga-Pieras C
Enferm Infecc Microbiol Clin; 2006 Apr; 24(4):225-31. PubMed ID: 16725081
[TBL] [Abstract][Full Text] [Related]
25. Drug resistance at low viraemia in HIV-1-infected patients with antiretroviral combination therapy.
Aleman S; Söderbärg K; Visco-Comandini U; Sitbon G; Sönnerborg A
AIDS; 2002 May; 16(7):1039-44. PubMed ID: 11953470
[TBL] [Abstract][Full Text] [Related]
26. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
[TBL] [Abstract][Full Text] [Related]
27. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
[TBL] [Abstract][Full Text] [Related]
28. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.
Masquelier B; Pereira E; Peytavin G; Descamps D; Reynes J; Verdon R; Fleury H; Garraffo R; Chêne G; Raffi F; Brun-Vézinet F;
J Clin Virol; 2005 May; 33(1):75-8. PubMed ID: 15797369
[TBL] [Abstract][Full Text] [Related]
29. Very high baseline HIV viremia impairs efficacy of non-nucleoside reverse transcriptase inhibitor-based ART: a long-term observation in treatment-naïve patients.
Chen S; Han Y; Song XJ; Li YL; Zhu T; Lu HZ; Tang XP; Zhang T; Zhao M; He Y; He SH; Wang M; Li YZ; Huang SB; Li Y; Liu J; Cao W; Li TS
Infect Dis Poverty; 2020 Jun; 9(1):75. PubMed ID: 32571409
[TBL] [Abstract][Full Text] [Related]
30. Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study.
Fehr J; Glass TR; Louvel S; Hamy F; Hirsch HH; von Wyl V; Böni J; Yerly S; Bürgisser P; Cavassini M; Fux CA; Hirschel B; Vernazza P; Martinetti G; Bernasconi E; Günthard HF; Battegay M; Bucher HC; Klimkait T;
J Transl Med; 2011 Jan; 9():14. PubMed ID: 21255386
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of drug resistance and importance of viral load measurements in Honduran HIV-infected patients failing antiretroviral treatment.
Murillo W; de Rivera IL; Parham L; Jovel E; Palou E; Karlsson AC; Albert J
HIV Med; 2010 Feb; 11(2):95-103. PubMed ID: 19686436
[TBL] [Abstract][Full Text] [Related]
32. Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment. Groupe d'Epidémiologie du SIDA en Aquitaine (GECSA).
Thiébaut R; Morlat P; Jacqmin-Gadda H; Neau D; Mercié P; Dabis F; Chêne G
AIDS; 2000 May; 14(8):971-8. PubMed ID: 10853978
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients.
Calcagno A; Motta I; Ghisetti V; Lo Re S; Allice T; Marinaro L; Milia MG; Tettoni MC; Trentini L; Orofino G; Salassa B; Di Perri G; Bonora S
AIDS Res Hum Retroviruses; 2015 Oct; 31(10):999-1008. PubMed ID: 26165150
[TBL] [Abstract][Full Text] [Related]
34. Clinically relevant thresholds for ultrasensitive HIV drug resistance testing: a multi-country nested case-control study.
Inzaule SC; Hamers RL; Noguera-Julian M; Casadellà M; Parera M; Kityo C; Steegen K; Naniche D; Clotet B; Rinke de Wit TF; Paredes R;
Lancet HIV; 2018 Nov; 5(11):e638-e646. PubMed ID: 30282603
[TBL] [Abstract][Full Text] [Related]
35. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients.
Zaccarelli M; Tozzi V; Lorenzini P; Trotta MP; Forbici F; Visco-Comandini U; Gori C; Narciso P; Perno CF; Antinori A;
AIDS; 2005 Jul; 19(10):1081-9. PubMed ID: 15958840
[TBL] [Abstract][Full Text] [Related]
36. Gender differences in HIV drug resistance mutations and virological outcome.
Mave V; Gahunia M; Frontini M; Clark R; Mushatt D
J Womens Health (Larchmt); 2011 Jan; 20(1):117-22. PubMed ID: 21190485
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy.
Angelis DS; Tateno AF; Diaz RS; Succi RC; Pannuti CS; Gouvea Ade F; Machado DM
Braz J Infect Dis; 2011; 15(1):60-5. PubMed ID: 21412591
[TBL] [Abstract][Full Text] [Related]
38. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study.
Torre D; Tambini R
HIV Clin Trials; 2002; 3(1):1-8. PubMed ID: 11819179
[TBL] [Abstract][Full Text] [Related]
39. Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.
Ortu M; Vitiello P; Adorni F; Rossotti R; Di Vincenzo P; Vigano O; Galli M; Rusconi S
Curr HIV Res; 2011 Dec; 9(8):625-9. PubMed ID: 22211659
[TBL] [Abstract][Full Text] [Related]
40. Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Ngo-Giang-Huong N; Wittkop L; Judd A; Reiss P; Goetghebuer T; Duiculescu D; Noguera-Julian A; Marczynska M; Giacquinto C; Ene L; Ramos JT; Cellerai C; Klimkait T; Brichard B; Valerius N; Sabin C; Teira R; Obel N; Stephan C; de Wit S; Thorne C; Gibb D; Schwimmer C; Campbell MA; Pillay D; Lallemant M;
BMC Infect Dis; 2016 Nov; 16(1):654. PubMed ID: 27825316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
